In 2021, a team led by neurosurgeon and engineer Ben Rapoport embarked on an ambitious journey to bridge the gap between artificial intelligence and human thought. Precision Neuroscience was born with a clear focus: improving the lives of people with severe neurological conditions through brain-computer interfaces (BCI). Less than three years later, the company has now raised a $102 million Series C round, marking a critical milestone in its mission and positioning itself firmly alongside, if not against, Elon Musk’s Neuralink.
The latest round, led by General Equity Holdings, comes with notable participation from Steadview Capital, B Capital, and the Duquesne Family Office, headed by prominent investor Stanley Druckenmiller. With this funding, Precision Neuroscience’s total capital
Cursor’s GPT-5 Moment Comes with a Margin Test
Mukundan Sivaraj
